Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen

被引：0
|
作者：
Davies, C [1 ]
机构：
[1] Univ Oxford, Studies Unit, Clin Trial Serv & Epidemiol, Oxford, England
来源：
CANCER TREATMENT REVIEWS | 2004年 / 30卷 / 06期
关键词：
D O I：
10.1016/j.ctrv.2004.06.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：583 / 588
页数：6
相关论文
共 50 条
  • [1] Switching to adjuvant exemestane after tamoxifen improves disease-free survival in postmenopausal women with hormone receptor-positive early breast cancer
    不详
    Drugs & Therapy Perspectives, 2007, 23 (5) : 1 - 4
  • [2] First mature survival analysis of the Intergroup Exemestane Study: A randomised trial in disease-free, postmenopausal patients with early breast cancer randomized to continue tamoxifen or switch to exemestane following an initial 2-3 years of adjuvant tamoxifen.
    Coombes, R. C.
    Paridaens, R.
    Jassem, J.
    Van de Velde, C. J.
    Delozier, T.
    Jones, S. E.
    Hall, E.
    Kilburn, L. S.
    Snowdon, C. F.
    Bliss, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 9S - 9S
  • [3] Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer
    Boccardo, F.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (02): : 76 - 77
  • [4] Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer
    Francesco Boccardo
    Nature Clinical Practice Oncology, 2008, 5 : 76 - 77
  • [5] Cost-effectiveness of switching to exemestane (EX) after 2-3 years of adjuvant tamoxifen (T) in postmenopausal (PM) early breast cancer (EBC)
    Pinto, C. G.
    Castanho, M. S.
    Miguel, L. S.
    Rocha, E.
    BREAST, 2007, 16 : S64 - S64
  • [6] Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
    Coombes, R. C.
    Kilburn, L. S.
    Snowdon, C. F.
    Paridaens, R.
    Coleman, R. E.
    Jones, S. E.
    Jassem, J.
    Van de Velde, C. J. H.
    Delozier, T.
    Alvarez, I.
    Del Mastro, L.
    Ortmann, O.
    Diedrich, K.
    Coates, A. S.
    Bajetta, E.
    Holmberg, S. B.
    Dodwell, D.
    Mickiewicz, E.
    Andersen, J.
    Lonning, P. E.
    Cocconi, G.
    Forbes, J.
    Castiglione, M.
    Stuart, N.
    Stewart, A.
    Fallowfield, L. J.
    Bertelli, G.
    Hall, E.
    Bogle, R. G.
    Carpentieri, M.
    Colajori, E.
    Subar, M.
    Ireland, E.
    Bliss, J. M.
    LANCET, 2007, 369 (9561): : 559 - 570
  • [7] Quality of life in the intergroup exemestane study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer
    Fallowfield, LJ
    Bliss, JM
    Porter, LS
    Price, MH
    Snowdon, CF
    Jones, SE
    Coombes, RC
    Hall, E
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 910 - 917
  • [8] Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study
    Mieog, J. Sven D.
    Morden, James P.
    Bliss, Judith M.
    Coombes, R. Charles
    van de Velde, Cornelis J. H.
    LANCET ONCOLOGY, 2012, 13 (04): : 420 - 432
  • [9] Exemestane therapy after 2 to 3 years of tamoxifen therapy improved survival compared with 5 years of tamoxifen therapy alone
    Coombes, RC
    Hall, E
    Gibson, LJ
    ANNALS OF INTERNAL MEDICINE, 2005, 143 (11) : 824 - 824
  • [10] Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer
    Risebrough, Nancy A.
    Verma, Shailendra
    Trudeau, Maureen
    Mittmann, Nicole
    CANCER, 2007, 110 (03) : 499 - 508
12345